BriaCell Soars 87.29% Post Reverse Split, Clinical Trial Progress

On April 24, 2025, BriaCell's stock surged by 87.29% in pre-market trading, marking a dramatic turnaround from its recent volatility.

BriaCell Therapeutics recently implemented a 1-for-15 reverse stock split, which has led to a significant reduction in the number of shares outstanding. This strategic move is often used to increase the stock price and attract new investors, but it can also indicate underlying financial challenges or strategic shifts within the company.

Despite the reverse split, BriaCell's Phase 3 clinical trial for Bria-IMT™ in combination with an immune checkpoint inhibitor for metastatic breast cancer has shown promising progress. The trial has seen an acceleration in patient enrollment, with over 75 patients now enrolled. This development is a positive indicator for the company's pipeline and could potentially drive future growth and investor confidence.